Search

Your search keyword '"Batstra, Manou"' showing total 32 results
Start Over Author "Batstra, Manou"
32 results on '"Batstra, Manou"'

1. An International Perspective on Preceding Infections in Guillain-Barre Syndrome The IGOS-1000 Cohort

Author

Leonhard, Sonja E., van der Eijk, Annemiek A., Andersen, Henning, Antonini, Giovanni, Arends, Samuel, Attarian, Shahram, Barroso, Fabio A., Bateman, Kathleen J., Batstra, Manou R., Benedetti, Luana, van den Berg, Bianca, Van den Bergh, Peter, Burmann, Jan, Busby, Mark, Casasnovas, Carlos, Cornblath, David R., Davidson, Amy, Doets, Alex Y., van Doorn, Pieter A., de la Cour, Charlotte Dornonville, Feasby, Thomas E., Fehmi, Janev, Garcia-Sobrino, Tania, Goldstein, Jonathan M., Gorson, Kenneth C., Granit, Volkan, Hadden, Robert D. M., Harbo, Thomas, Hartung, Hans-Peter, Hasan, Imran, Holbech, Jakob, V, Holt, James K. L., Jahan, Israt, Islam, Zhahirul, Karafiath, Summer, Katzberg, Hans D., Kleyweg, Ruud P., Kolb, Noah, Kuitwaard, Krista, Kuwahara, Motoi, Kusunoki, Susumu, Luijten, Linda W. G., Kuwabara, Satoshi, Pan, Edward Lee, Lehmann, Helmar C., Maas, Marijke, Martin-Aguilar, Lorena, Al Miller, James, Mohammad, Quazi Deen, Monges, Soledad, Nedkova-Hristova, Velina, Nobile-Orazio, Eduardo, Pardo, Julio, Pereon, Yann, Querol, Luis, Reisin, Ricardo, Van Rijs, Wouter, Rinaldi, Simon, Roberts, Rhys C., Roodbol, Joyce, Shahrizaila, Nortina, Sindrup, Soren Hein, Stein, Beth, Cheng-Yin, Tan, Tankisi, Hatice, Tio-Gillen, Anne P., Tous, Maria J. Sedano, Verboon, Christine, Vermeij, Frederique H., Visser, Leo H., Huizinga, Ruth, Willison, Hugh J., Jacobs, Bart C., Leonhard, Sonja E., van der Eijk, Annemiek A., Andersen, Henning, Antonini, Giovanni, Arends, Samuel, Attarian, Shahram, Barroso, Fabio A., Bateman, Kathleen J., Batstra, Manou R., Benedetti, Luana, van den Berg, Bianca, Van den Bergh, Peter, Burmann, Jan, Busby, Mark, Casasnovas, Carlos, Cornblath, David R., Davidson, Amy, Doets, Alex Y., van Doorn, Pieter A., de la Cour, Charlotte Dornonville, Feasby, Thomas E., Fehmi, Janev, Garcia-Sobrino, Tania, Goldstein, Jonathan M., Gorson, Kenneth C., Granit, Volkan, Hadden, Robert D. M., Harbo, Thomas, Hartung, Hans-Peter, Hasan, Imran, Holbech, Jakob, V, Holt, James K. L., Jahan, Israt, Islam, Zhahirul, Karafiath, Summer, Katzberg, Hans D., Kleyweg, Ruud P., Kolb, Noah, Kuitwaard, Krista, Kuwahara, Motoi, Kusunoki, Susumu, Luijten, Linda W. G., Kuwabara, Satoshi, Pan, Edward Lee, Lehmann, Helmar C., Maas, Marijke, Martin-Aguilar, Lorena, Al Miller, James, Mohammad, Quazi Deen, Monges, Soledad, Nedkova-Hristova, Velina, Nobile-Orazio, Eduardo, Pardo, Julio, Pereon, Yann, Querol, Luis, Reisin, Ricardo, Van Rijs, Wouter, Rinaldi, Simon, Roberts, Rhys C., Roodbol, Joyce, Shahrizaila, Nortina, Sindrup, Soren Hein, Stein, Beth, Cheng-Yin, Tan, Tankisi, Hatice, Tio-Gillen, Anne P., Tous, Maria J. Sedano, Verboon, Christine, Vermeij, Frederique H., Visser, Leo H., Huizinga, Ruth, Willison, Hugh J., and Jacobs, Bart C.

Abstract

Background and Objectives Infections play a key role in the development of Guillain-Barre syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale. Methods We analyzed the first 1,000 patients included in the International GBS Outcome Study with available biosamples (n = 768) for the presence of a recent infection with Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus. Results Serologic evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%), and Epstein-Barr virus in 7 (1%) patients. Evidence of more than 1 recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing positive or negative for a recent infection. The proportions of infections were similar across continents. The sensorimotor variant and the demyelinating electrophysiologic subtype were most frequent across all infection groups, although proportions were significantly higher in patients with a cytomegalovirus and significantly lower in those with a C. jejuni infection. C. jejuni-positive patients were more severely affected, indicated by a lower Medical Research Council sum score at nadir (p = 0.004) and a longer time to regain the ability to walk independently (p = 0.005). The pure motor variant and axonal electrophysiologic subtype were more frequent in Asian compared with American or European C. jejuni-positive patients (p < 0.001, resp. p = 0.001). Time to nadir was longer in the cytomegalovirus-positive patients (p = 0.004). Discussion Across geographical regions, the distribution o

Published
2022

2. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020

Author

Van Walle, Ivo, Leitmeyer, Katrin, Broberg, Eeva K, Van Esbroeck, Marjan, Beuselinck, Kurt, Vermeersch, Pieter, Karagiannis, Christos, Mentis, Andreas, Lampropoulou, Stavroula, Erlund, Iris, Melin, Merit, Ekström, Nina, Vihervaara, Terhi, Gaymard, Alexandre, Frobert, Emilie, Escuret, Vanessa, Kurolt, Ivan-Christian, Fournier, Guillaume, Abdelrahman, Tamir, Nguyen, Trung, Klak, Adrian, Bos, Anne E, Russcher, Anne, van ’t Veen, Annemarie, Stemerding, Annette M, van Corteveen-Splinter, Annette, van Hees, Babette C, Wintermans, Bas B, Herpers, Bjorn L, Reusken, Chantal BEM, van der Donk, Christel FM, Oliveira dos Santos, Claudy, GeurtsvanKessel, Corine H, Timmerman, Cornelis P, Ong, David SY, Kaersenhout, Deborah J, van Lochem, Ellen, Geeraedts, Felix, Rijkers, Ger T, Berkhout, Hannke, Koeleman, Hans GM, van Loo, Inge HM, Rahamat-Langendoen, Janette, Murk, Jean-Luc, Tjhie, Jeroen HT, Kissing, Johan, Reimerink, Johan, Kerremans, Jos J, de Vries, Jutte JC, Heemstra, Karen A, Thai, Khoa TD, Jim, Kin Ki, Mulder, Leontine, van den Beld, Maaike JC, Batstra, Manou R, Konstantinovski, Maria M, Wegdam-Blans, Marjolijn CA, Hoogewerf, Martine, de Graaf, Melanie J, de Jong, Menno D., Heron, Michiel, van Rijn, Michiel, Heusinkveld, Moniek, Van Burgel, Nathalie, Savelkoul, Paul HM, den Reijer, Paul Martijn, Wever, Peter C, Croughs, Peter, Zonneveld, Rens, van Gyseghem, Sim, Thijsen, Steven FT, Stoof, Susanne P, Jurriaans, Suzanne, Debast, Sylvia B, Mank, Theo, Hira, Vishal, Michalski, Aleksander, Siewierska-Puchlerska, Anna, Gajda, Ewa, Paciorek, Jarosław, Pakieła, Marta, Kołakowska-Kulesza, Agnieszka, Pancer, Katarzyna, Nowakowska, Magdalena, Costa, Inês, Zé-Zé, Líbia, Guiomar, Raquel, Hammas, Berit, Öckinger, Johan Brynedal, Prosenc, Katarina, and Berginc, Nataša

Subjects
Infecções Respiratórias, medicine.medical_specialty, Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), diagnostic, specificity, Sensitivity and Specificity, Gastroenterology, Asymptomatic, Nucleic Acids, Virology, Internal medicine, medicine, Humans, media_common.cataloged_instance, European union, Pandemics, media_common, Infecções Sistémicas e Zoonoses, accuracy, biology, SARS-CoV-2, business.industry, Research, Public Health, Environmental and Occupational Health, COVID-19, sensitivity, Confidence interval, meta-analysis, Study heterogeneity, Meta-analysis, biology.protein, Nucleic acid, Antibody Tests, Antibody, medicine.symptom, business
Abstract

Background Reliable testing for SARS-CoV-2 is key for the management of the COVID-19 pandemic. Aim We estimate diagnostic accuracy for nucleic acid and antibody tests 5 months into the COVID-19 pandemic, and compare with manufacturer-reported accuracy. Methods We reviewed the clinical performance of SARS-CoV-2 nucleic acid and antibody tests based on 93,757 test results from 151 published studies and 20,205 new test results from 12 countries in the European Union and European Economic Area (EU/EEA). Results Pooling the results and considering only results with 95% confidence interval width ≤ 5%, we found four nucleic acid tests, including one point-of-care test and three antibody tests, with a clinical sensitivity ≥ 95% for at least one target population (hospitalised, mild or asymptomatic, or unknown). Nine nucleic acid tests and 25 antibody tests, 12 of them point-of-care tests, had a clinical specificity of ≥ 98%. Three antibody tests achieved both thresholds. Evidence for nucleic acid point-of-care tests remains scarce at present, and sensitivity varied substantially. Study heterogeneity was low for eight of 14 sensitivity and 68 of 84 specificity results with confidence interval width ≤ 5%, and lower for nucleic acid tests than antibody tests. Manufacturer-reported clinical performance was significantly higher than independently assessed in 11 of 32 and four of 34 cases, respectively, for sensitivity and specificity, indicating a need for improvement in this area. Conclusion Continuous monitoring of clinical performance within more clearly defined target populations is needed.

Published
2021
Full Text
View/download PDF

3. Antecedent infections in Guillain‐Barré syndrome in endemic areas of arbovirus transmission: A multinational case‐control study

Author

Leonhard, Sonja E., primary, Tan, Cheng Yin, additional, Eijk, Annemiek A., additional, Reisin, Ricardo R., additional, Franken, Suzanne C., additional, Huizinga, Ruth, additional, Arends, Samuel, additional, Batstra, Manou R., additional, Bezerra Jeronimo, Selma M., additional, Drenthen, Judith, additional, Koning, Laura, additional, Leon Cejas, Luciana, additional, Marchesoni, Cintia, additional, Marques, Wilson, additional, Shahrizaila, Nortina, additional, Casas, Dardo F., additional, Sotelo, Andrea, additional, Tillard, Belen, additional, Dourado, Mario‐Emilio, additional, and Jacobs, Bart C., additional

Published
2021
Full Text
View/download PDF

4. Antecedent infections in Guillain-Barré syndrome in endemic areas of arbovirus transmission:A multinational case-control study

Author

Leonhard, Sonja E., Tan, Cheng Yin, van der Eijk, Annemiek A., Reisin, Ricardo R., Franken, Suzanne C., Huizinga, Ruth, Arends, Samuel, Batstra, Manou R., Bezerra Jeronimo, Selma M., Drenthen, Judith, de Koning, Laura, Leon Cejas, Luciana, Marchesoni, Cintia, Marques, Wilson, Shahrizaila, Nortina, Casas, Dardo F., Sotelo, Andrea, Tillard, Belen, Dourado, Mario Emilio, Jacobs, Bart C., Leonhard, Sonja E., Tan, Cheng Yin, van der Eijk, Annemiek A., Reisin, Ricardo R., Franken, Suzanne C., Huizinga, Ruth, Arends, Samuel, Batstra, Manou R., Bezerra Jeronimo, Selma M., Drenthen, Judith, de Koning, Laura, Leon Cejas, Luciana, Marchesoni, Cintia, Marques, Wilson, Shahrizaila, Nortina, Casas, Dardo F., Sotelo, Andrea, Tillard, Belen, Dourado, Mario Emilio, and Jacobs, Bart C.

Abstract

Half of the world's population is at risk of arthropod-borne virus (arbovirus) infections. Several arbovirus infections have been associated with Guillain-Barré syndrome (GBS). We investigated whether arboviruses are driving GBS beyond epidemic phases of transmission and studied the antibody response to glycolipids. The protocol of the International Guillain-Barré syndrome Outcome Study (IGOS), an observational prospective cohort study, was adapted to a case-control design. Serum samples were tested for a recent infection with Zika virus (ZIKV), dengue virus (DENV), chikungunya (CHIKV) virus, hepatitis E virus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), Campylobacter jejuni, and Mycoplasma pneumoniae, and for antibodies to glycolipids. Forty-nine patients were included from Brazil (63%), Argentina (14%), and Malaysia (22%). Evidence of a recent infection was found in 27/49 (55%) patients: C jejuni (n = 15, 31%), M pneumoniae (n = 5, 10%), CHIKV (n = 2, 4%), EBV (n = 1, 2%), C jejuni and M pneumoniae (n = 2, 4%), CMV and DENV (n = 1, 2%), and C jejuni and DENV (n = 1, 2%). In 22 patients, 35 paired controls were collected. Odds ratio for recent infections did not significantly differ between cases and controls. No typical anti-ganglioside antibody binding was associated with recent arbovirus infection. We conclude that arbovirus infections occur in GBS patients outside of epidemic viral transmission, although not significantly more than in controls. Broad infection and anti-ganglioside antibody serology are important to establish the most likely pathogenic trigger in GBS patients. Larger studies are necessary to determine the association between arboviruses and GBS.

Published
2021

8. Multilaboratory Comparison of Pneumococcal Multiplex Immunoassays Used in lmmunosurveillance of Streptococcus pneumoniae across Europe

Author

Meek, Bob, Ekstrom, Nina, Kantso, Bjorn, Almond, Rachael, Findlow, Jamie, Gritzfeld, Jenna F, Jorgensen, Charlotte Svaerke, Ljungberg, Karl, Atterfelt, Fredrik, Batstra, Manou R, Andeweg, Kevin, de Jong, Ben AW, Prince, Harry E, Lape-Nixon, Mary, Gageldonk, Pieter GM, Tcherniaeva, Irina, Aaberge, Ingeborg, Herstad, Tove Karin, Melin, Merit, Rijkers, Ger T, Berbers, Guy A, Wehlin, Lena, Ljungman, Margaretha, Thorstensson, Rigmor, Aktas, Teodora, Virta, Camilla, Merit, Melin, Dik, Wim, Almond, Rachel, Faustini, Sian, Richter, Alex, Goldblatt, David, Burbidge, Polly, Bossuyt, Xavier, Zborowsky, Tomasz, Bennink, Erik, Akowitz, Alfred, McGuire, Richard, Kristoffersen, Anne-Cathrine, Sinnadura, Kalpana, Assay, EU Pneumo Multiplex, Immunology, and Bossuyt, Xavier

Subjects
0301 basic medicine, Pneumococcal serotypes, Serotype, ANALYTICAL VARIABILITY, lcsh:QR1-502, VACCINE, medicine.disease_cause, DISEASE, lcsh:Microbiology, Serology, Clinical Science and Epidemiology, immunoserology, 0302 clinical medicine, Medicine, ASSAY, Multiplex, 030212 general & internal medicine, Immunoassay, Antibodies, Bacterial, QR1-502, Europe, serosurveillance, Streptococcus pneumoniae, Epidemiological Monitoring, Life Sciences & Biomedicine, Research Article, concordance, medicine.medical_specialty, multiplex immunoassay, QUANTITATION, ASSIGNMENT, Serogroup, Microbiology, Pneumococcal Infections, POLYSACCHARIDES, 03 medical and health sciences, ANTIBODY UNITS, Humans, quantitative methods, Medical physics, Molecular Biology, Protocol (science), Science & Technology, interlaboratory comparison, IGG, business.industry, Reproducibility of Results, STANDARD REFERENCE SERUM, Immune surveillance, capsular polysaccharide, 030104 developmental biology, Antibody response, IgG antibodies, business
Abstract

Serology of Streptococcus pneumoniae is challenging due to existence of multiple clinically relevant serotypes and the introduction of multivalent vaccines in national immunization programs. Multiplex immunoassays (MIAs) are applied as high-throughput cost-effective methods for serosurveillance, and yet laboratories use their own protocols. The aims of this study were to assess the agreement of results generated by MIAs in different laboratories within the EU Pneumo Multiplex Assay Consortium, to analyze factors contributing to differences in outcome, and to create a harmonized protocol. The study demonstrated good agreement of results of MIAs performed by laboratories using controlled assays for determination of levels of vaccine-induced pneumococcal antibodies. The EU Pneumo Multiplex Assay Consortium is open to everyone working in public health services, and it aims to facilitate efforts by participants to run and maintain a cost-effective, reproducible, high-quality MIA platform., Surveillance studies are required to estimate the impact of pneumococcal vaccination in both children and the elderly across Europe. The World Health Organization (WHO) recommends use of enzyme immunoassays (EIAs) as standard methods for immune surveillance of pneumococcal antibodies. However, as levels of antibodies to multiple serotypes are monitored in thousands of samples, a need for a less laborious and more flexible method has evolved. Fluorescent-bead-based multiplex immunoassays (MIAs) are suitable for this purpose. An increasing number of public health and diagnostic laboratories use MIAs, although the method is not standardized and no international quality assessment scheme exists. The EU Pneumo Multiplex Assay Consortium was initiated in 2013 to advance harmonization of MIAs and to create an international quality assessment scheme. In a multilaboratory comparison organized by the consortium, agreement among nine laboratories that used their own optimized MIA was assessed on a panel of 15 reference sera for 13 pneumococcal serotypes with the new WHO standard 007sp. Agreement was assessed in terms of assay accuracy, reproducibility, repeatability, precision, and bias. The results indicate that the evaluated MIAs are robust and reproducible for measurement of vaccine-induced antibody responses. However, some serotype-specific variability in the results was observed in comparisons of polysaccharides from different sources and of different conjugation methods, especially for serotype 4. On the basis of the results, the consortium has contributed to the harmonization of MIA protocols to improve reliability of immune surveillance of Streptococcus pneumoniae. IMPORTANCE Serology of Streptococcus pneumoniae is challenging due to existence of multiple clinically relevant serotypes and the introduction of multivalent vaccines in national immunization programs. Multiplex immunoassays (MIAs) are applied as high-throughput cost-effective methods for serosurveillance, and yet laboratories use their own protocols. The aims of this study were to assess the agreement of results generated by MIAs in different laboratories within the EU Pneumo Multiplex Assay Consortium, to analyze factors contributing to differences in outcome, and to create a harmonized protocol. The study demonstrated good agreement of results of MIAs performed by laboratories using controlled assays for determination of levels of vaccine-induced pneumococcal antibodies. The EU Pneumo Multiplex Assay Consortium is open to everyone working in public health services, and it aims to facilitate efforts by participants to run and maintain a cost-effective, reproducible, high-quality MIA platform.

Published
2020

9. An International Perspective on Preceding Infections in Guillain-Barré Syndrome

Author

Leonhard, Sonja E., van der Eijk, Annemiek A., Andersen, Henning, Antonini, Giovanni, Arends, Samuel, Attarian, Shahram, Barroso, Fabio A., Bateman, Kathleen J., Batstra, Manou R., Benedetti, Luana, van den Berg, Bianca, Van den Bergh, Peter, Bürmann, Jan, Busby, Mark, Casasnovas, Carlos, Cornblath, David R., Davidson, Amy, Doets, Alex Y., van Doorn, Pieter A., Dornonville de la Cour, Charlotte, Feasby, Thomas E., Fehmi, Janev, Garcia-Sobrino, Tania, Goldstein, Jonathan M., Gorson, Kenneth C., Granit, Volkan, Hadden, Robert D.M., Harbo, Thomas, Hartung, Hans-Peter, Hasan, Imran, Holbech, Jakob V., Holt, James K.L., Jahan, Israt, Islam, Zhahirul, Karafiath, Summer, Katzberg, Hans D., Kleyweg, Ruud P., Kolb, Noah, Kuitwaard, Krista, Kuwahara, Motoi, Kusunoki, Susumu, Luijten, Linda W.G., Kuwabara, Satoshi, Lee Pan, Edward, Lehmann, Helmar C., Maas, Marijke, Martín-Aguilar, Lorena, Miller, James A.L., Mohammad, Quazi Deen, Monges, Soledad, Nedkova-Hristova, Velina, Nobile-Orazio, Eduardo, Pardo, Julio, Pereon, Yann, Querol, Luis, Reisin, Ricardo, Van Rijs, Wouter, Rinaldi, Simon, Roberts, Rhys C., Roodbol, Joyce, Shahrizaila, Nortina, Sindrup, Søren Hein, Stein, Beth, Cheng-Yin, Tan, Tankisi, Hatice, Tio-Gillen, Anne P., Sedano Tous, María J., Verboon, Christine, Vermeij, Frederique H., Visser, Leo H., Huizinga, Ruth, Willison, Hugh J., and Jacobs, Bart C.

Published
2022
Full Text
View/download PDF

10. Preceding infections in Guillain-Barre syndrome: Results from the IGOS-1000 cohort

Author

Leonhard, Sonja, van der Eijk, Annemiek, Arends, Samuel, Bateman, Kathleen, Batstra, Manou, Van den Bergh, Peter, Chavada, Govindsinh, Cornblath, David, Doets, Alex, Van Doorn, Pieter, Efthimios, Dardiotis, Feasby, Tom, Gorson, Ken, Harbo, Thomas, Hartung, Hans-Peter, Huizinga, Ruth, Hshieh, Sung-Tsang, Hughes, Richard, Islam, Zhahirul, Kusunoki, Susumu, Lehmann, Helmar, Maas, Marijke, Mohammad, Quazi Deen, Nobile-Orazio, Eduardo, Pereon, Yann, Querol, Luis, Reddel, Stephen, Reisin, Ricardo, Shahrizaila, Nortina, Willison, Hugh, Jacobs, Bart, Leonhard, Sonja, van der Eijk, Annemiek, Arends, Samuel, Bateman, Kathleen, Batstra, Manou, Van den Bergh, Peter, Chavada, Govindsinh, Cornblath, David, Doets, Alex, Van Doorn, Pieter, Efthimios, Dardiotis, Feasby, Tom, Gorson, Ken, Harbo, Thomas, Hartung, Hans-Peter, Huizinga, Ruth, Hshieh, Sung-Tsang, Hughes, Richard, Islam, Zhahirul, Kusunoki, Susumu, Lehmann, Helmar, Maas, Marijke, Mohammad, Quazi Deen, Nobile-Orazio, Eduardo, Pereon, Yann, Querol, Luis, Reddel, Stephen, Reisin, Ricardo, Shahrizaila, Nortina, Willison, Hugh, and Jacobs, Bart

Published
2020

11. IgE cross-reactivity measurement of cashew nut, hazelnut and peanut using a novel IMMULITE inhibition method

Author

Bastiaan-Net, Shanna, Batstra, Manou R., Aazamy, Nasrin, Savelkoul, Huub F.J., Van Der Valk, Johanna P.M., Gerth Van Wijk, Roy, Schreurs, Marco W.J., Wichers, Harry J., De Jong, Nicolette W., Bastiaan-Net, Shanna, Batstra, Manou R., Aazamy, Nasrin, Savelkoul, Huub F.J., Van Der Valk, Johanna P.M., Gerth Van Wijk, Roy, Schreurs, Marco W.J., Wichers, Harry J., and De Jong, Nicolette W.

Abstract

Tree nut-allergic individuals are often sensitised towards multiple nuts and seeds. The underlying cause behind a multi-sensitisation for cashew nut, hazelnut, peanut and birch pollen is not always clear. We investigated whether immunoglobulin E antibody (IgE) cross-reactivity between cashew nut, hazelnut and peanut proteins exists in children who are multi-allergic to these foods using a novel IMMULITE®-based inhibition methodology, and investigated which allergens might be responsible. In addition, we explored if an allergy to birch pollen might play a role in this co-sensitisation for cashew nut, hazelnut and peanut. Serum of five children with a confirmed cashew nut allergy and suffering from allergic symptoms after eating peanut and hazelnut were subjected to inhibition immunoassays using the IMMULITE® 2000 XPi. Serum-specific IgE (sIgE) to seed storage allergens and pathogenesis-related protein 10 (PR10) allergens were determined and used for molecular multicomponent allergen correlation analyses with observed clinical symptoms and obtained inhibition data. IgE cross-reactivity was observed in all patients. Hazelnut extract was a strong inhibitor of cashew nut sIgE (46.8%), while cashew nut extract was less able to inhibit hazelnut extract (22.8%). Peanut extract showed the least inhibition potency. Moreover, there are strong indications that a birch pollen sensitisation to Bet v 1 might play a role in the observed symptoms provoked upon ingestion of cashew nut and hazelnut. By applying an adjusted working protocol, the IMMULITE® technology can be used to perform inhibition assays to determine the risk of sIgE cross-reactivity between very different food components.

Published
2020

14. Multilaboratory Comparison of Pneumococcal Multiplex Immunoassays Used in Immunosurveillance of Streptococcus pneumoniae across Europe

Author

Meek, Bob, primary, Ekström, Nina, additional, Kantsø, Bjørn, additional, Almond, Rachael, additional, Findlow, Jamie, additional, Gritzfeld, Jenna F., additional, Sværke Jørgensen, Charlotte, additional, Ljungberg, Karl, additional, Atterfelt, Fredrik, additional, Batstra, Manou R., additional, Andeweg, Kevin, additional, de Jong, Ben A. W., additional, Prince, Harry E., additional, Lapé-Nixon, Mary, additional, Gageldonk, Pieter G. M., additional, Tcherniaeva, Irina, additional, Aaberge, Ingeborg, additional, Herstad, Tove Karin, additional, Melin, Merit, additional, Rijkers, Ger T., additional, and Berbers, Guy A., additional

Published
2019
Full Text
View/download PDF

18. Endophthalmitis after strabismus surgery: incidence and outcome in relation to age, operated eye muscle, surgical technique, scleral perforation and immune state.

Author

Simonsz, Huibert J., Rutar, Tina, Kraft, Stephen, Thiadens, Alberta A.H.J., Batstra, Manou R., Verdijk, Robert M., Loeffler, Karin U., Kommerell, Guntram, Berg, Mariette Swart‐van den, Schooneveld, Mary J, Drunen, Lamberdina C.J.W, Missotten, Luc, Kolling, Gerold H, Tusscher, Marcel P.M., Morad, Yair, Nucci, Paolo, Olitsky, Scott E, Kowal, Lionel, Eppinga, Hessel G, and Duivenboden, Frank

Subjects
EYE muscles, OPERATIVE surgery, STRABISMUS, AGE distribution, OLDER patients, SURGERY, MYRINGOPLASTY
Abstract

Purpose: Identify risk factors for endophthalmitis after strabismus surgery (EASS) and relate these to incidence and outcome. Methods: Ophthalmologists, who had operated, diagnosed or treated EASS, completed a case record form with 71 questions in six domains: Preoperative, Surgery, Perforation, Postoperative, Outcome and Experts' opinion. To estimate the age‐specific incidence per number of strabismus operations in the Netherlands during 1994‐2013, the age distribution of Dutch cases was compared with the age‐specific rates of strabismus surgery in the Dutch Registry of Strabismus Operations and with population data. Exploratory data analysis was performed. The immune state was evaluated in six patients. Five enucleated eyes were studied histopathologically. Results: None of the 26 patients (27 eyes with EASS) were between 9 and 65 years old, except for one patient with retinal haemorrhage followed by endophthalmitis. In the Netherlands during 1994‐2013, the rate of EASS was approximately one per 11 000 strabismus operations, but one per 4300 for children aged 0–3 and one per 1000 for patients 65 and older. Endophthalmitis was diagnosed on postoperative day 1–4 in children aged 0–3. In all 15 children aged 0–5, the 16 affected eyes were phthisical, eviscerated or enucleated. The involved eye muscle had been recessed in 25 of 27 cases. It was a medial rectus in 15 of 16 children aged 0–6. It was a lateral (6), inferior (2) or medial (1) rectus in elderly. Scleral perforation went unnoticed in all children (no record in three) and in two of seven elderly (no record in two). Histopathology showed transscleral scarring compatible with scleral perforation in four patients but, in a two‐year‐old girl who had EASS together with a transient medial rectus palsy, the sclera underneath the former suture tract was not perforated but did contain the long posterior ciliary artery. Conclusions: Endophthalmitis after strabismus surgery (EASS) affects children and elderly, with a grave outcome in young children. It occurs after recession of the medial rectus muscle in children, and it may occur without scleral perforation. Age and perforation are key determinants that interact with other factors that determine the occurrence and fulminance of EASS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Screening for GAD Antibodies in the General Population--Influence of Age and Neuroendocrine Conditions on Threshold Definition and False Positivity

Author

BATSTRA, MANOU R, DRIEL, ARIANNE, PETERSEN, JACOB S, DRENTH, PATRICIA P, DONSELAAR, CEES A, TOL, MAARTEN J, BRUINING, G JAN, GROBBEE, DIEDERICK E, DYRBERG, THOMAS, and AANSTOOT, HENK-JAN

Subjects
Diabetes -- Research, Health
Abstract

Population based prediction of type I diabetes has become available with the development of radiobinding assays (RBA)for GAD and IA2 antibodies. However, the sensitivity and specificity of screening in the [...]

Published
1999

22. Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease?

Author

Weersma, Rinse K, Batstra, Manou R, Kleibeuker, Jan H, van Dullemen, Hendrik M, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Center for Liver, Digestive and Metabolic Diseases (CLDM)

Subjects
Adult, Male, Middle Aged, digestive system diseases, Crohn Disease, Pancreatitis, Seroepidemiologic Studies, Case-Control Studies, Azathioprine, Humans, Female, Pancreas, Immunosuppressive Agents, Autoantibodies
Abstract

CONTEXT: Azathioprine is frequently used in the treatment of Crohn's disease. A severe side effect is acute pancreatitis, which is specific for Crohn's disease. Autoantibodies against exocrine pancreas occur in about 30% of Crohn's disease cases but not in other inflammatory diseases. Pancreatic autoantibody positive Crohn's disease patients might have a low grade inflammation of the pancreas which may be aggravated by the introduction of azathioprine, resulting in clinically overt acute pancreatitis. OBJECTIVE: We hypothesized that the presence of pancreatic autoantibodies in Crohn's disease patients is associated with the development of azathioprine-induced pancreatitis. PARTICIPANTS: Eight patients with Crohn's disease and azathioprine-induced pancreatitis and 26 patients with Crohn's disease not using azathioprine. MAIN OUTCOME MEASURE: Pancreatic autoantibodies were determined by a standardized immunofluorescence method. RESULTS: Two out of 8 patients with azathioprine-induced pancreatitis were positive for pancreatic autoantibodies (25.0%), detectable in serum dilutions of 1:40 and 1:160, respectively. In the control group of Crohn's disease patients, two (7.7%) were positive in serum dilutions of 1:2. All positive samples had an extracellular fluorescence pattern. The difference in the prevalence of pancreatic autoantibodies was not statistically significant (P=0.229). CONCLUSIONS: We could not confirm our hypothesis that most or all patients with azathioprine-induced pancreatitis were pancreatic autoantibody positive. The prevalence of pancreatic autoantibodies in the Crohn's disease patients in our group was lower than in previous reports.This study does not support an association between pancreatic autoantibodies and azathioprine-induced pancreatitis in Crohn's disease. However, this association should not be definitively excluded and larger, preferably prospective, studies are needed.

Published
2008

30. Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: Association with IA-2 and islet cell autoantibodies

Author

Winnock, Frederic, Christie, Michael R., Batstra, Manou R., Aanstoot, Henk-Jan, Weets, Ilse, Decochez, Katelijn, Jopart, Philippe, Nicolaij, Dany, Gorus, Frans K., Winnock, Frederic, Christie, Michael R., Batstra, Manou R., Aanstoot, Henk-Jan, Weets, Ilse, Decochez, Katelijn, Jopart, Philippe, Nicolaij, Dany, and Gorus, Frans K.

Abstract

OBJECTIVE - To study the association of autoantibodies against a 38-kDa glycated islet cell membrane-associated (GLIMA) protein with (pre)type 1 diabetes, patient characteristics, and other immune and genetic markers of the disease and to evaluate the possible added value of GLIMA antibody determinations for disease prediction and classification. RESEARCH DESIGN AND METHODS - Recent-onset type 1 diabetic patients (n = 100), prediabetic siblings (n = 23), and nondiabetic control subjects (n = 100) were consecutively recruited by the Belgian Diabetes Registry. GLIMA antibodies were determined by immunoprecipitation of radiolabeled islet cell proteins; islet cell antibodies (ICAs) were determined by indirect immunofluorescence; and insulin autoantibodies (IAAs), insulinoma-associated protein-2 antibodies (IA-2As), and GAD antibodies (GADAs) were determined by radioligand assays. RESULTS - GLIMA antibodies were detected in 38% of type 1 diabetic patients and 35 of prediabetic siblings (during follow-up) vs. 0% in control subjects (P < 0.001). Their prevalence was lower than that of other antibodies and was significantly associated with high levels of 1A-2A and ICA (P < 0.0001). In (pre)diabetes, GLIMA antibodies could only be demonstrated in sera positive for ≥1 other autoantibody. CONCLUSIONS - GLIMA antibodies are strongly associated with type 1 diabetes and antibody markers of rapid progression to clinical onset but have a lower diagnostic sensitivity for the disease than IAA, ICA, IA-2A, or GADA. In its present form, the GLIMA antibody assay does not provide much additional information for prediction or classification of diabetes, compared with that obtained from the measurement of IA-2As alone or in combination with IAAs, ICAs, and GADAs.

31. Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease?

Author

Weersma RK, Batstra MR, Kleibeuker JH, and van Dullemen HM

Subjects
Adult, Autoantibodies blood, Case-Control Studies, Crohn Disease complications, Crohn Disease epidemiology, Female, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Pancreatitis immunology, Seroepidemiologic Studies, Autoantibodies metabolism, Azathioprine adverse effects, Azathioprine therapeutic use, Crohn Disease drug therapy, Pancreas immunology, Pancreatitis chemically induced
Abstract

Context: Azathioprine is frequently used in the treatment of Crohn's disease. A severe side effect is acute pancreatitis, which is specific for Crohn's disease. Autoantibodies against exocrine pancreas occur in about 30% of Crohn's disease cases but not in other inflammatory diseases. Pancreatic autoantibody positive Crohn's disease patients might have a low grade inflammation of the pancreas which may be aggravated by the introduction of azathioprine, resulting in clinically overt acute pancreatitis., Objective: We hypothesized that the presence of pancreatic autoantibodies in Crohn's disease patients is associated with the development of azathioprine-induced pancreatitis., Participants: Eight patients with Crohn's disease and azathioprine-induced pancreatitis and 26 patients with Crohn's disease not using azathioprine., Main Outcome Measure: Pancreatic autoantibodies were determined by a standardized immunofluorescence method., Results: Two out of 8 patients with azathioprine-induced pancreatitis were positive for pancreatic autoantibodies (25.0%), detectable in serum dilutions of 1:40 and 1:160, respectively. In the control group of Crohn's disease patients, two (7.7%) were positive in serum dilutions of 1:2. All positive samples had an extracellular fluorescence pattern. The difference in the prevalence of pancreatic autoantibodies was not statistically significant (P=0.229)., Conclusions: We could not confirm our hypothesis that most or all patients with azathioprine-induced pancreatitis were pancreatic autoantibody positive. The prevalence of pancreatic autoantibodies in the Crohn's disease patients in our group was lower than in previous reports.This study does not support an association between pancreatic autoantibodies and azathioprine-induced pancreatitis in Crohn's disease. However, this association should not be definitively excluded and larger, preferably prospective, studies are needed.

Published
2008

32. The association between autoimmune thyroiditis, autoimmune gastritis and type 1 diabetes.

Author

Lam-Tse WK, Batstra MR, Koeleman BP, Roep BO, Bruining MG, Aanstoot HJ, and Drexhage HA

Subjects
Animals, Diabetes Mellitus, Type 1 immunology, Gastritis immunology, Humans, Diabetes Mellitus, Type 1 etiology, Gastritis complications, Thyroiditis, Autoimmune complications
Abstract

Type 1 diabetes mellitus (DM1), autoimmune thyroid disease (ATD) and autoimmune gastritis often occur together forming the so-called autoimmune polyendocrine syndrome (APS) type 3. Thyroid autoimmunity is evident in up to one third and gastric autoimmunity in up to a quarter of patients with DM1. Also relatives of DM1 patients, particularly mothers, have higher frequencies of these autoimmune conditions. Vice versa, gastric autoimmunity is present in one third of ATD patients and islet autoimmunity in one out ten. The BB-DP rat, the NOD mouse, the OS chicken and the neonatal thymectomy mouse model are animal models of APS type 3. In these models the autoimmune destruction of the various target tissues has been shown to be a multi-step process in which several genetic polymorphisms need to converge to induce both local anomalies in the target gland and anomalies in the immune system. With regard to environmental factors, excess iodine is well known to elicit/aggravate thyroid autoimmunity in these animal models. Screening DM1 patients and their relatives (particularly females) for thyroid autoimmunity is recommended. If positive, excess iodine should be avoided and thyroxin treatment considered. Whether autoimmune thyroiditis and autoimmune gastritis patients should be screened for islet Ab is not clarified.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results